{ "brief_id": "SPR-2026-2D9D", "generated_at": "2026-04-19", "domains": [ "Evolutionary Biology", "Mycology" ], "original_hypothesis": "Applying the evolutionary framework of 'budding speciation'—where a new species arises from a small, isolated subpopulation—to understand the emergence and spread of antifungal resistance in pathogenic fungal populations.", "grounding": { "novelty_assessment": { "score": 0.85, "closest_existing_work": [ { "paper_id": "1a6f939e76900682f9a09d6ad21321a97793493c", "title": "The existence of species rests on a metastable equilibrium between inbreeding and outbreeding. An essay on the close relationship between speciation, inbreeding and recessive mutations", "doi": "10.1186/1745-6150-6-62", "year": 2010, "similarity": "conceptual", "key_difference": "Joly (2010) proposes a general model of speciation via 'budding' from an ancestral stock, driven by inbreeding. The SPORE hypothesis specifically applies this evolutionary framework to the emergence of antifungal resistance in pathogenic fungi, proposing a detailed mechanism involving genetic drift in small, isolated subpopulations (e.g., biofilms, host niches) and subsequent spread via introgression, which is not addressed in Joly's paper.", "authors": [ "E. Joly" ] }, { "paper_id": "dc4af46d28060cb799cf3fe6c3f31e337e91e1ba", "title": "Microbial species and intraspecies units exist and are maintained by ecological cohesiveness coupled to high homologous recombination", "doi": "10.1038/s41467-024-53787-0", "year": 2024, "similarity": "mechanistic", "key_difference": "Conrad et al. (2024) describe how microbial species and intraspecies units are maintained by ecological cohesiveness and recombination. While this supports the idea of gene flow (recombination) shaping populations, it does not specifically model the initial emergence of a trait (like resistance) via a stochastic budding event from a small founder population, which is the core of the SPORE hypothesis.", "authors": [ "R. Conrad", "Catherine E. Brink", "Tomeu Viver", "L. Rodriguez-R.", "Borja Aldeguer-Riquelme", "J. Hatt", "S. Venter", "Ramon Rossello-Mora", "Rudolf I. Amann", "Konstantinos T. Konstantinidis" ] } ], "verdict": "novel" }, "evidence_base": [ { "paper_id": "1a6f939e76900682f9a09d6ad21321a97793493c", "title": "The existence of species rests on a metastable equilibrium between inbreeding and outbreeding. An essay on the close relationship between speciation, inbreeding and recessive mutations", "doi": "10.1186/1745-6150-6-62", "year": 2010, "citation_count": 22, "support_type": "analogous", "relevance": "Provides the foundational evolutionary concept of 'budding speciation' where new species arise from small, inbreeding groups derived from an ancestral stock. This is the core model being transferred to mycology.", "key_finding": "Proposes a model where new species arise not by population splitting, but by small inbreeding groups 'budding' from an ancestral stock, driven by a metastable equilibrium between inbreeding and outbreeding.", "authors": [ "E. Joly" ] }, { "paper_id": "dc4af46d28060cb799cf3fe6c3f31e337e91e1ba", "title": "Microbial species and intraspecies units exist and are maintained by ecological cohesiveness coupled to high homologous recombination", "doi": "10.1038/s41467-024-53787-0", "year": 2024, "citation_count": 14, "support_type": "indirect", "relevance": "Supports the 'post-divergence gene flow' component of the hypothesis by demonstrating that high homologous recombination is a key mechanism maintaining microbial species and intraspecies units, which aligns with the idea of resistance alleles spreading via introgression.", "key_finding": "Shows that microbial species and subspecies (genomovars) are maintained by ecological cohesiveness coupled with frequent and unbiased homologous recombination, which facilitates gene flow.", "authors": [ "R. Conrad", "Catherine E. Brink", "Tomeu Viver", "L. Rodriguez-R.", "Borja Aldeguer-Riquelme", "J. Hatt", "S. Venter", "Ramon Rossello-Mora", "Rudolf I. Amann", "Konstantinos T. Konstantinidis" ] }, { "paper_id": "520ddf7230d7a3594eff1018ba0a090f1fa93ccc", "title": "Genomic Diversity across Candida auris Clinical Isolates Shapes Rapid Development of Antifungal Resistance In Vitro and In Vivo", "doi": "10.1128/mbio.00842-22", "year": 2022, "citation_count": 64, "support_type": "indirect", "relevance": "Demonstrates that high genomic diversity in C. auris populations provides a substrate for rapid, multiple-pathway evolution of resistance. This pre-existing variation is a prerequisite for the 'random fixation of pre-existing genetic variants' proposed in the budding model.", "key_finding": "Clinical isolates of Candida auris show significant genomic diversity, and resistance to fluconazole can evolve rapidly via multiple genetic pathways in vitro and in vivo.", "authors": [ "Laura S. Burrack", "R. Todd", "Natthapon Soisangwan", "N. Wiederhold", "Anna M. Selmecki" ] }, { "paper_id": "9085db641326b99e647209094f6fb2862fef2b72", "title": "Genomic epidemiology and antifungal resistance of emerging Trichophyton indotineae in China", "doi": "10.1080/22221751.2025.2498571", "year": 2025, "citation_count": 8, "support_type": "tangential", "relevance": "While focused on tracing the spread of an already-resistant lineage, its use of genomic epidemiology on a global collection of isolates is the type of study that could, in principle, be used to detect patterns consistent with a budding origin (e.g., identifying a small, ancestral subpopulation). It does not test the hypothesis directly.", "key_finding": "Genomic analysis of T. indotineae isolates from China and globally characterizes mutations and copy number variations associated with resistance, and performs phylogenetic analysis to understand spread.", "authors": [ "Wenting Xie", "Guanzhao Liang", "Xue Kong", "Clement K. M. Tsui", "Xiaodong She", "Wei-Da Liu", "Xiaofang Li" ] }, { "paper_id": "9962d16b8c9c2a54b075899de7d6389ebab70ac1", "title": "Two chromosome-level genome assemblies of Rhodiola shed new light on genome evolution in rapid radiation and evolution of the biosynthetic pathway of salidroside.", "doi": "10.1111/tpj.16501", "year": 2023, "citation_count": 11, "support_type": "tangential", "relevance": "The paper is cited in the hypothesis as an example of detailed genomic analysis of budding speciation in plants (Rhodiola). It provides the methodological analogy (comparative genomics) but does not discuss budding speciation or resistance evolution.", "key_finding": "Provides high-quality genome assemblies for Rhodiola species, enabling comparative genomic analysis of adaptation and rapid radiation, but does not explicitly discuss the budding speciation model.", "authors": [ "Dan Zhang", "Xiao-Ying Liu", "Lin-Feng Qiu", "Zhao Liu", "Ya-Peng Yang", "Long Huang", "Shi-Yu Wang", "Jian‐Qiang Zhang" ] } ], "counter_evidence": [ { "paper_id": "4aec2405145df31795b53e66b0b6970ef56ea438", "title": "Cytotoxicity and resistance evolution of a novel antifungal carbon nanoparticle", "doi": "10.1101/2024.02.11.579833", "finding": "Shows that yeast populations can rapidly adapt to novel antifungal carbon dots through laboratory evolution experiments. This demonstrates strong, direct selection can drive resistance evolution quickly in a large population, which is the traditional model the SPORE hypothesis seeks to complement/reframe.", "severity": "addressable", "authors": [ "Sijan Poudel Sharma", "Suraj Paudyal", "Justin B. Domena", "Yiqun Zhou", "Elliot Cleven", "Christian Agatemor", "J. D. Van Dyken", "R. Leblanc" ] }, { "paper_id": "520ddf7230d7a3594eff1018ba0a090f1fa93ccc", "title": "Genomic Diversity across Candida auris Clinical Isolates Shapes Rapid Development of Antifungal Resistance In Vitro and In Vivo", "doi": "10.1128/mbio.00842-22", "finding": "Demonstrates rapid evolution of resistance under strong antifungal selection in experimental settings, supporting a classic selective sweep model. This does not contradict the budding hypothesis but shows an alternative, likely common, pathway.", "severity": "minor", "authors": [ "Laura S. Burrack", "R. Todd", "Natthapon Soisangwan", "N. Wiederhold", "Anna M. Selmecki" ] } ], "gap_manifest_update": { "closed_gaps": [], "new_gaps": [ "Lack of direct empirical studies in mycology that test for the signature of a 'budding' event (e.g., severe bottleneck, drift, then introgression) in the evolutionary history of a known antifungal resistance trait. All provided papers on fungal resistance describe patterns consistent with selection or spread, not the stochastic origin proposed.", "No population genetic models in the provided literature formally adapt the plant-based 'budding speciation' model for fungal life histories (e.g., haploidy, clonality, mixed mating systems). The competence gap remains open." ], "data_available": [ "Genomic datasets from papers like 'Genomic epidemiology and antifungal resistance of emerging Trichophyton indotineae in China' (paper_id: 9085db641326b99e647209094f6fb2862fef2b72) and 'Genomic Diversity across Candida auris...' (paper_id: 520ddf7230d7a3594eff1018ba0a090f1fa93ccc) could be re-analyzed with population genetic statistics (e.g., tests for bottlenecks, patterns of introgression) to search for signals consistent with the budding hypothesis. However, they are not longitudinal and lack dense sampling of the putative progenitor population at the initial emergence point." ] }, "search_queries": [ { "query": "budding speciation fungal pathogens", "type": "novelty", "rationale": "Direct search for the core hypothesis linking the evolutionary model to mycology." }, { "query": "founder effect antifungal resistance evolution", "type": "novelty", "rationale": "Tests if the specific mechanism of stochastic origin via bottlenecks is documented." }, { "query": "genetic drift azole resistance emergence", "type": "novelty", "rationale": "Searches for evidence of non-selective, stochastic processes in resistance evolution." }, { "query": "introgression antifungal resistance spread", "type": "novelty", "rationale": "Tests the 'post-divergence gene flow' component of the hypothesis for spreading alleles." }, { "query": "Candida biofilm population bottleneck genomics", "type": "evidence", "rationale": "Seeks evidence for small, isolated subpopulations (biofilms) with founder effects in fungi." }, { "query": "standing genetic variation antifungal resistance", "type": "evidence", "rationale": "Looks for pre-existing polymorphisms that could be randomly fixed via drift in a bud." }, { "query": "fungal hybridization drug resistance transfer", "type": "evidence", "rationale": "Seeks evidence for gene flow/introgression as a mechanism for spreading resistance alleles." }, { "query": "clonal expansion vs selection resistance", "type": "evidence", "rationale": "Investigates alternative models to selective sweeps in resistance emergence." }, { "query": "Rhodiola budding speciation genomics", "type": "cross_domain", "rationale": "Finds the foundational plant studies on the model to understand its genetic mechanisms." }, { "query": "peripatric speciation microbial pathogens", "type": "cross_domain", "rationale": "Searches for application of similar speciation models (small isolate origin) in other microbes like bacteria." }, { "query": "founder effect antibiotic resistance evolution", "type": "cross_domain", "rationale": "Looks for a direct precedent of the proposed mechanism in bacterial systems, a closely related field." } ] }, "sharpened": { "title": "Stochastic emergence of antifungal resistance via population bottleneck-driven fixation and subsequent introgression in pathogenic fungi", "formal_statement": "If a pathogenic fungal population experiences a severe bottleneck (effective population size Nₑ = 50-200) in an isolated niche, then genetic drift will fix pre-existing resistance alleles with low selective coefficients (|s| < 0.01) at a probability ≥ 0.05, significantly exceeding expectations under selection alone. Subsequent gene flow via homologous recombination (rate ≥ 10⁻⁸ events/bp/generation) will introgress these alleles into the larger progenitor population, creating phylogenetic reticulations detectable by discordance ≥ 15% between gene trees.", "independent_variables": [ { "name": "Bottleneck effective population size (Nₑ)", "type": "continuous", "range": "50-200", "unit": "number of individuals" }, { "name": "Pre-bottleneck allele frequency of resistance variants", "type": "continuous", "range": "0.001-0.05", "unit": "frequency" }, { "name": "Selection coefficient (s) of resistance allele in absence of drug", "type": "continuous", "range": "-0.02 to +0.01", "unit": "dimensionless" }, { "name": "Homologous recombination rate", "type": "continuous", "range": "10⁻⁹ to 10⁻⁷", "unit": "events/base pair/generation" } ], "dependent_variables": [ { "name": "Probability of allele fixation in bottleneck population", "type": "continuous", "expected_direction": "increase", "unit": "probability (0-1)" }, { "name": "Time to allele fixation in progenitor population post-introgression", "type": "continuous", "expected_direction": "decrease", "unit": "generations" }, { "name": "Phylogenetic discordance between resistance locus and housekeeping genes", "type": "continuous", "expected_direction": "increase", "unit": "percentage of discordant nodes" }, { "name": "Minimum inhibitory concentration (MIC) distribution in progenitor population", "type": "continuous", "expected_direction": "non-monotonic", "unit": "μg/mL" } ], "proposed_mechanism": { "causal_chain": [ "Step 1: A subpopulation of a pathogenic fungus (e.g., Candida auris) becomes isolated in a niche (e.g., biofilm, specific host tissue) with reduced effective population size (Nₑ = 50-200).", "Step 2: In this bottleneck, genetic drift dominates over selection for alleles with |s| < 0.01, leading to stochastic fixation of pre-existing resistance variants (e.g., ERG11 mutations) present at low frequency (0.001-0.05).", "Step 3: Subsequent contact and gene flow (homologous recombination rate ≥ 10⁻⁸) between the bottleneck-derived lineage and the larger progenitor population introgresses the fixed resistance allele.", "Step 4: Introgression creates phylogenetic network reticulations, with discordance ≥ 15% between trees built from resistance loci versus neutral genomic regions." ], "key_assumptions": [ "Resistance alleles exist at low frequencies in ancestral populations due to mutation-selection balance or fluctuating selection.", "Bottleneck events are common in clinical/ecological settings (e.g., transmission between hosts, biofilm formation).", "Homologous recombination occurs at sufficient rates to transfer large genomic regions containing resistance alleles.", "The fitness cost of resistance (s in drug-free conditions) is small enough (|s| < 0.02) that drift can overcome selection in small populations." ], "known_unknowns": [ "The exact distribution of fitness effects (DFE) for resistance mutations in relevant in vivo conditions.", "The quantitative relationship between Nₑ in clinical niches and measurable census population sizes.", "The rate of recombination between divergent fungal lineages in natural and host environments." ] }, "falsifiable_predictions": [ { "prediction": "In experimental bottlenecks of Nₑ = 100, the fixation probability of a resistance allele with s = -0.005 will be ≥ 0.05, exceeding the probability under strong selection (s > 0.1) in large populations.", "quantitative_bound": "Fixation probability 0.05-0.10 vs. <0.001 under deterministic selection", "measurement_method": "Fluctuation assay with whole-population sequencing across 100 replicate bottleneck lineages", "null_hypothesis": "H0: Fixation probability in bottlenecks is ≤ fixation probability under selection in large populations (s > 0.1).", "statistical_test": "One-tailed Fisher's exact test, alpha=0.05, power=0.8 (requires n=100 replicates per condition)" }, { "prediction": "In phylogenomic analyses of resistant clinical isolates, gene trees containing resistance alleles will show ≥ 15% topological discordance with species trees based on 100 conserved housekeeping genes.", "quantitative_bound": "15-40% discordance in nodes with bootstrap support >70%", "measurement_method": "Maximum likelihood phylogenies from whole-genome sequences, measured by Robinson-Foulds distance", "null_hypothesis": "H0: Topological discordance between resistance gene trees and species trees is ≤ 5%.", "statistical_test": "Permutation test of tree distances with 1000 replicates, alpha=0.01" }, { "prediction": "Following experimental introgression, the time to reach 50% frequency of a resistance allele in a large recipient population (Nₑ = 10⁴) will be reduced by ≥ 30% compared to de novo mutation under identical selection pressure (s = 0.05).", "quantitative_bound": "Reduction from 1000 to ≤700 generations", "measurement_method": "Long-term evolution experiment with periodic whole-genome sequencing and recombination quantification via SNP linkage decay", "null_hypothesis": "H0: Time to 50% frequency via introgression is ≥ time via de novo mutation.", "statistical_test": "Log-rank test for frequency trajectories, alpha=0.05" } ], "boundary_conditions": [ { "condition": "Bottleneck size Nₑ > 500", "justification": "Above this threshold, selection dominates over drift for alleles with |s| > 0.001, making stochastic fixation negligible" }, { "condition": "Selection coefficient |s| > 0.02 in the absence of drug", "justification": "Strongly deleterious alleles are purged even in small populations; strongly beneficial alleles fix deterministically" }, { "condition": "Recombination rate < 10⁻¹⁰ events/bp/generation", "justification": "Below this rate, introgression is negligible compared to new mutation as a source of variation" }, { "condition": "Population subdivision with FST < 0.25 between subpopulations", "justification": "High gene flow prevents the establishment of significant allele frequency differences via drift" } ], "theoretical_framework": "Nearly Neutral Theory of Molecular Evolution (Ohta) combined with Founder Effect Speciation (Mayr) and Network Phylogenetics" }, "protocol": { "protocol_title": "Protocol for validating stochastic antifungal resistance emergence via bottleneck-driven fixation and introgression", "overall_timeline": "8-14 months", "overall_budget_estimate": "€20k-80k", "phases": [ { "phase_number": 1, "phase_name": "In Silico Validation", "objective": "Determine if genetic drift in simulated bottlenecks (Nₑ=50-200) can fix low-frequency resistance alleles (|s|<0.01) with probability ≥0.05, and if resulting phylogenetic patterns match clinical isolate data.", "methodology": "1. Wright-Fisher forward simulations using SLiM v4.2 to model bottleneck dynamics. Parameters: Nₑ=50-200, s=[-0.02, +0.01], initial allele frequency=0.001-0.05. 1000 replicates per parameter combination. 2. Analysis of publicly available Candida auris/Trichophyton indotineae genomes from NCBI SRA (BioProjects PRJNA485481, PRJNA949202) using IQ-TREE2 for phylogenies and PhyloNet for network analysis. Calculate Robinson-Foulds distances between gene trees (ERG11, FKS1) and species trees (100 housekeeping genes).", "required_resources": { "equipment": [ "High-performance computing cluster or cloud instance (AWS EC2 r6i.xlarge)" ], "software": [ "SLiM v4.2", "IQ-TREE2", "PhyloNet", "R v4.3 with ape, phytools, ggtree packages", "bcftools/samtools" ], "datasets": [ "NCBI SRA: Candida auris genomes (PRJNA485481), Trichophyton indotineae (PRJNA949202), CGD database for resistance loci" ], "competences": [ "Population genetics simulation", "Phylogenomic analysis", "Bioinformatics scripting (Python/R)" ], "estimated_cost": "€500-2000 (cloud computing + software licenses)", "estimated_duration": "4-6 weeks" }, "expected_outputs": [ "Output 1: Distribution of fixation probabilities across parameter space, confirming if P(fixation)≥0.05 for |s|<0.01 in bottlenecks.", "Output 2: Quantified phylogenetic discordance (Robinson-Foulds distances) from clinical isolates, testing if ≥15% of nodes discordant." ], "success_criteria": [ { "metric": "Fixation probability for s=-0.005, Nₑ=100", "threshold": "≥0.05 (vs. <0.001 for s>0.1 in large populations)", "measurement": "Proportion of 1000 simulations where allele reaches frequency=1" }, { "metric": "Phylogenetic discordance in clinical isolates", "threshold": "≥15% nodes discordant (bootstrap>70%)", "measurement": "Robinson-Foulds distance normalized by total nodes between resistance gene trees and species trees" } ], "go_nogo_decision": { "go_if": "Both criteria met: simulations show P(fixation)≥0.05 AND clinical data show ≥15% discordance", "nogo_if": "Simulations show P(fixation)<0.01 OR clinical discordance <5% with high confidence (p<0.01)", "pivot_if": "Only one criterion met: reconsider parameter ranges or focus on specific fungal species showing signal" }, "risks": [ { "risk": "Public genomes lack sufficient metadata to infer bottlenecks", "probability": "medium", "mitigation": "Use simulated data with realistic demographic models from literature; focus on isolates from known bottleneck scenarios (single-patient outbreaks)" }, { "risk": "Computational time exceeds estimates for large simulations", "probability": "low", "mitigation": "Use approximate coalescent simulations (msprime) for exploratory runs before full SLiM simulations" } ] }, { "phase_number": 2, "phase_name": "Minimal Experimental Validation", "objective": "Empirically test if bottleneck of Nₑ~100 in Candida auris leads to stochastic fixation of a marked resistance allele with known small fitness cost.", "methodology": "1. Engineer a C. auris strain (B8441 background) with a neutral marker (mCherry) linked to a resistance allele (fluconazole resistance via ERG11^Y132F) with measured s=-0.005 in drug-free medium. 2. Perform 100 replicate bottleneck experiments: inoculate 100 cells from a large population (initial allele frequency=0.01) into 100 separate wells, grow to saturation (~20 generations), sequence entire population (Illumina MiSeq 2x150bp) to determine fixation. 3. Control: large population (Nₑ>10⁴) replicates under identical conditions.", "required_resources": { "equipment": [ "Biosafety Level 2 lab", "Microplate reader (Tecan Spark)", "Illumina MiSeq", "Microbial incubator", "Flow cytometer (for mCherry sorting)" ], "software": [ "bcl2fastq", "breseq for variant calling", "R for statistical analysis" ], "datasets": [ "C. auris reference genome (CBS10913)", "Engineered strain genotype" ], "competences": [ "Fungal genetics (CRISPR-Cas9 editing)", "Microbial evolution experiment design", "NGS library prep and analysis" ], "estimated_cost": "€8k-15k (strain engineering, sequencing, consumables)", "estimated_duration": "2-3 months" }, "expected_outputs": [ "Output 1: Fixation frequency in bottleneck vs. large population replicates.", "Output 2: Direct measurement of selection coefficient in drug-free medium via growth competition assays." ], "success_criteria": [ { "metric": "Fixation probability in bottlenecks (Nₑ=100)", "threshold": "≥0.05", "measurement": "Proportion of 100 bottleneck replicates where resistance allele frequency >0.95" }, { "metric": "Difference from large population controls", "threshold": "Odds ratio ≥5 (Fisher's exact test p<0.05)", "measurement": "Comparison of fixation counts between bottleneck and large population conditions" } ], "go_nogo_decision": { "go_if": "Bottleneck fixation probability ≥0.05 AND significantly higher than large population controls (p<0.05)", "nogo_if": "No fixation events in bottlenecks OR no difference from controls (p>0.1)", "pivot_if": "Fixation occurs but at lower probability (0.01-0.04): adjust bottleneck size or test allele with different s" }, "risks": [ { "risk": "Engineered resistance allele has higher |s| than intended, dominating dynamics", "probability": "medium", "mitigation": "Precisely measure s via 5 replicate competition assays before bottleneck experiment; use multiple alleles if needed" }, { "risk": "Bottleneck size not accurately controlled due to growth variation", "probability": "low", "mitigation": "Use flow cytometry to precisely inoculate 100 cells; include viability staining" } ] }, { "phase_number": 3, "phase_name": "Full Experimental Protocol", "objective": "Validate complete causal chain: bottleneck fixation → introgression via recombination → spread in recipient population with phylogenetic discordance.", "methodology": "1. Evolve 10 independent bottleneck lineages from Phase 2 where resistance fixed. 2. Co-culture each bottleneck lineage with a genetically distinct, susceptible progenitor strain (marked with GFP) under conditions promoting recombination (biofilm, host-mimicking media). Measure recombination rates via loss of marker linkage using whole-genome sequencing (PacBio HiFi). 3. Track introgression in large recipient populations (Nₑ=10⁴) under fluconazole selection (0.5×MIC). Sample every 50 generations for 500 generations, sequence pools to measure allele frequency trajectories. 4. Construct phylogenies from evolved isolates (10× coverage Illumina) for resistance loci vs. housekeeping genes.", "required_resources": { "equipment": [ "PacBio Sequel IIe for recombination detection", "Illumina NextSeq 2000 for time-series sequencing", "Continuous culture devices (chemostats or morbidostats)", "Confocal microscope for biofilm imaging" ], "software": [ "pbmm2, pbsv for PacBio analysis", "GATK for variant calling", "ClonalFrameML for recombination detection", "BEAST2 for phylogenetic dating" ], "datasets": [ "Time-series allele frequency data", "Full genome sequences of all evolved isolates" ], "competences": [ "Long-term evolution experiments", "Recombination rate quantification", "Population genomic analysis", "Phylogenetic network modeling" ], "estimated_cost": "€50k-100k+ (long-term culturing, extensive sequencing, personnel)", "estimated_duration": "9-12 months" }, "expected_outputs": [ "Output 1: Recombination rates between lineages and evidence of introgression tracts.", "Output 2: Time to 50% frequency in recipient population with/without introgression.", "Output 3: Phylogenetic networks showing discordance between resistance and housekeeping gene trees." ], "success_criteria": [ { "metric": "Time to 50% frequency with introgression", "threshold": "≥30% reduction vs. de novo mutation control", "measurement": "Generations until allele frequency >0.5 in recipient population (log-rank test)" }, { "metric": "Phylogenetic discordance in evolved populations", "threshold": "≥15% discordant nodes (bootstrap>70%)", "measurement": "Robinson-Foulds distance between trees from resistance loci vs. 10 housekeeping genes" }, { "metric": "Recombination rate", "threshold": "≥10⁻⁸ events/bp/generation", "measurement": "From ClonalFrameML analysis of PacBio data on co-cultured populations" } ], "go_nogo_decision": { "go_if": "All three criteria met: faster spread via introgression, measurable recombination, and phylogenetic discordance", "nogo_if": "Introgression provides no speed advantage (≤10% reduction) OR recombination rate <10⁻¹⁰", "pivot_if": "Partial success: recombination occurs but no discordance—focus on population genetic signatures rather than phylogenetics" }, "risks": [ { "risk": "Recombination rates too low to detect introgression in experimental timeframe", "probability": "medium", "mitigation": "Use hyper-recombining strains or induce recombination via stress (UV, MMS); extend co-culture duration" }, { "risk": "Contamination or cross-talk between evolution lines", "probability": "low", "mitigation": "Physical separation, unique barcodes for each lineage, regular sterility checks" } ] } ], "phase_1_quick_start": { "can_start_today": true, "first_action": "Download Candida auris genome data from NCBI SRA (PRJNA485481) using sratoolkit and run IQ-TREE2 on ERG11 gene sequences to build initial gene tree.", "tools_needed": [ "sratoolkit", "fastq-dump", "Trimmomatic", "SPAdes", "prokka", "IQ-TREE2" ], "open_data_sources": [ "NCBI SRA (PRJNA485481, PRJNA949202)", "Candida Genome Database", "MycoCosm" ] } }, "panel": { "reviews": [ { "reviewer_persona": "methodologist", "overall_score": 8.2, "verdict": "accept", "strengths": [ "Le protocole adopte une approche progressive et prudente, avec une phase in silico pour valider les prédictions théoriques avant de s'engager dans des expériences coûteuses et longues. Ce design séquentiel avec des critères GO/NO-GO explicites est une excellente pratique méthodologique.", "La conception expérimentale intègre des contrôles appropriés à chaque phase (ex: populations larges en Phase 2, contrôle par mutation de novo en Phase 3) et utilise des réplicats biologiques en nombre élevé (100 lignées de goulot d'étranglement), ce qui renforce la validité interne et la robustesse des conclusions.", "L'hypothèse est formulée de manière précise et falsifiable, avec des prédictions quantitatives claires et des méthodes de mesure adéquates (probabilité de fixation, distances de Robinson-Foulds, suivi de fréquence allélique). La distinction entre les effets de la dérive et de la sélection est bien articulée." ], "weaknesses": [ "La puissance statistique pour la Phase 2, bien que raisonnable (100 réplicats), pourrait être marginale pour détecter une probabilité de fixation de 0.05. Avec P=0.05, on s'attend à ~5 événements de fixation sur 100. Une fluctuation aléatoire pourrait facilement donner 2-3 événements, menant à un faux NO-GO. Une analyse de puissance préalable plus formelle est nécessaire.", "Le risque de biais de mesure dans la Phase 3 est sous-estimé. Le suivi de la fréquence allélique par séquençage de pools tous les 50 générations peut manquer des dynamiques transitoires ou être biaisé par des différences d'efficacité d'amplification. Un contrôle par séquençage d'isolats individuels à des points clés serait un complément utile.", "Le protocole repose fortement sur la mesure précise du coefficient de sélection (s = -0.005) pour l'allèle de résistance marqué. Une erreur dans cette mesure (risque noté [medium]) invaliderait l'interprétation centrale de la Phase 2. La méthode pour mesurer 's' n'est pas décrite et devrait être détaillée, avec une estimation de l'intervalle de confiance." ], "critical_questions": [ "Pour la Phase 2, quel est le plan d'analyse statistique exact pour comparer la probabilité de fixation entre les goulots d'étranglement et les populations larges ? Un test exact de Fisher sur une table de contingence 2x2 (fixé vs non-fixé ; goulot vs large) est-il prévu, et sa puissance a-t-elle été calculée compte tenu du faible nombre d'événements attendus ?", "Dans la Phase 3, comment allez-vous isoler et quantifier spécifiquement l'effet de l'introgression par recombinaison homologue, par rapport à d'autres mécanismes potentiels de transfert génétique (ex: conversion génique, transfert horizontal de chromosomes) ou à une sélection secondaire sur des mutations compensatrices ? Le design avec marqueurs liés est bon, mais des contrôles additionnels pourraient être nécessaires.", "Le critère de discordance phylogénétique (≥15% des nœuds) est-il biologiquement pertinent et statistiquement robuste ? Avez-vous prévu une analyse de sensibilité pour ce seuil, et comment allez-vous distinguer une discordance due à l'introgression d'une discordance due à une évolution convergente ou à une saturation mutationnelle sur le gène de résistance ?" ], "recommendation": "Je recommande l'acceptation du protocole avec des révisions mineures. Le design est globalement solide, novateur et méthodologiquement rigoureux. Avant de commencer la Phase 2, il est impératif de : 1) réaliser une analyse de puissance statistique formelle et d'envisager d'augmenter le nombre de réplicats à 150-200 pour la condition goulot d'étranglement ; 2) détailler et valider le protocole de mesure du coefficient de sélection (s) avec réplicats techniques et biologiques. La Phase 3 devrait inclure un plan de contrôle supplémentaire pour vérifier le mécanisme de recombinaison homologue (par exemple, en invalidant un gène clé de la recombinaison dans une lignée témoin).", "confidence": 0.88 }, { "reviewer_persona": "domain_expert", "overall_score": 7.0, "verdict": "weak_accept", "confidence": 0.8, "strengths": [ "L'hypothèse intègre avec succès trois cadres théoriques bien établis mais souvent distincts — la théorie quasi neutre (Ohta), la dynamique de l'effet fondateur et des goulots d'étranglement (Mayr), et la phylogénétique de réseau — en un modèle mécaniste cohérent pour un problème appliqué pressant (la résistance aux antifongiques). Cette synthèse est intellectuellement convaincante.", "Le mécanisme proposé est biologiquement plausible et s'accorde avec l'écologie fongique connue. La reconnaissance des niches cliniques et écologiques (biofilms, tissus spécifiques) comme sites potentiels de goulots d'étranglement sévères est judicieuse et témoigne d'une compréhension de la biologie des populations fongiques allant au-delà des simples modèles in vitro.", "Le cadre quantitatif (Nₑ = 50-200, |s| < 0,01, taux de recombinaison ≥ 10⁻⁸) fournit des prédictions testables et fait sortir l'hypothèse d'un modèle purement verbal. La prédiction d'une discordance phylogénétique ≥ 15 % constitue un résultat concret et falsifiable pour les études génomiques." ], "weaknesses": [ "La base de preuves est davantage analogique que directe. L'article fondateur (Joly, 2010) traite d'un modèle général de spéciation, et non de l'évolution de la résistance chez les champignons. Les autres citations fournissent un contexte étayant (diversité, recombinaison, épidémiologie) mais ne constituent pas des preuves de la chaîne causale proposée. L'hypothèse manque actuellement de soutien empirique direct issu de systèmes fongiques.", "Les paramètres clés sont présentés comme des postulats mais constituent des inconnues critiques. La Distribution of Fitness Effects (DFE) des mutations de résistance aux antifongiques in vivo est mal caractérisée ; certaines mutations de résistance peuvent avoir |s| >> 0,01, rendant improbable une fixation médiée par la dérive. De même, le taux de recombinaison entre lignées divergentes en conditions naturelles est souvent bien inférieur à 10⁻⁸, ce qui pourrait rompre l'étape d'introgression.", "L'hypothèse peut sous-estimer le rôle de la sélection directe. En contexte clinique, les goulots d'étranglement (par exemple, la transmission) coïncident souvent avec l'exposition aux médicaments (prophylaxie ou traitement), créant un scénario où la sélection pour la résistance est forte et simultanée. Distinguer les effets de la dérive d'une sélection de fond faible dans ces environnements complexes constitue un défi méthodologique majeur." ], "critical_questions": [ "Étant donné que de nombreuses mutations de résistance aux antifongiques (par exemple, dans ERG11) sont connues pour conférer des coûts de fitness significativement supérieurs à 1 % in vitro, comment le postulat central de |s| < 0,01 peut-il être justifié pour les allèles pertinents dans les environnements de niche proposés ? Pouvez-vous fournir des estimations issues de la littérature ou des données préliminaires ?", "L'hypothèse postule que l'introgression par recombinaison homologue constitue une étape finale clé. Cependant, de nombreux champignons pathogènes comme Candida auris présentent des structures de population majoritairement clonales, avec une recombinaison limitée entre les principaux clades. Comment le mécanisme se déroulerait-il chez de telles espèces, ou l'hypothèse est-elle spécifique aux pathogènes qui se recombinent ?", "Comment distinguer opérationnellement la signature de ce modèle « goulot d'étranglement–fixation–introgression » de modèles alternatifs, tels que (a) la sélection sur la variation préexistante dans une grande population, ou (b) la mutation de novo et la sélection au cours de l'événement de goulot d'étranglement lui-même, à l'aide de jeux de données génomiques standard (par exemple, une collection d'isolats cliniques) ?" ], "recommendation": "L'hypothèse présente une synthèse novatrice et théoriquement solide qui mérite d'être étudiée. Je recommande de poursuivre avec un programme de recherche ciblé pour tester ses postulats centraux. La priorité devrait être accordée à : 1) Quantifier les effets sur la fitness des allèles de résistance dans des conditions pertinentes imitant l'hôte et sans médicament, afin d'affiner la DFE. 2) Développer des simulations de génomique des populations pour établir les signaux phylogénétiques attendus (discordance de réseau) sous ce modèle par rapport aux alternatives. 3) Le séquençage ciblé de populations fongiques issues de niches putatives de goulot d'étranglement (par exemple, des biofilms sur un hôte unique au cours du temps) afin de rechercher des preuves directes de décalages de fréquence allélique induits par la dérive." }, { "reviewer_persona": "contrarian", "overall_score": 4.5, "verdict": "weak_reject", "confidence": 0.85, "strengths": [ "L'hypothèse établit élégamment un pont entre la théorie de la génétique des populations (dérive dans les goulots d'étranglement) et un problème clinique pressant (résistance aux antifongiques), en proposant une voie non adaptative souvent négligée.", "Les prédictions proposées sont formulées de manière quantitative et testables en principe, dépassant les observations purement corrélationnelles pour proposer des expériences spécifiques et des signatures bio-informatiques." ], "weaknesses": [ "FAIL REASON #1: Le taux de recombinaison proposé (≥ 10⁻⁸ événements/bp/génération) est probablement insuffisant pour une introgression efficace dans le laps de temps proposé. De nombreux champignons pathogènes, dont Candida auris, présentent des structures de population majoritairement clonales, avec une recombinaison rare et restreinte. La probabilité qu'un allèle rare, ayant dérivé dans une minuscule sous-population, se recombine avec succès dans un fond génétique progéniteur génétiquement distinct avant d'être à nouveau perdu est extrêmement faible, ce qui fait de la chaîne causale allant de l'étape 3 à l'étape 4 le point de rupture critique.", "FAIL REASON #2: La distribution supposée du coût de fitness (|s| < 0,01) est optimiste et probablement irréaliste pour de nombreux allèles de résistance dans un environnement *sans médicament*, qui est la condition pertinente pour que la dérive l'emporte sur la sélection. Les mutations connues d'ERG11 portent souvent un coût de fitness mesurable in vitro. Si le coût réel est s = -0,05, et non -0,005, la dérive dans un Nₑ de 200 devient négligeable, et l'allèle est éliminé même dans le goulot d'étranglement.", "FAIL REASON #3: La discordance phylogénétique prédite (≥ 15 %) est un motif post-hoc attendu de nombreux processus (par exemple, évolution convergente, transfert horizontal de gènes, tri de lignées incomplet). Sa détection ne valide pas le mécanisme de goulot d'étranglement-introgression proposé. Il s'agit d'une prédiction soumise à des facteurs de confusion ; l'hypothèse manque d'une signature unique et falsifiable permettant de distinguer son mécanisme spécifique de ces alternatives." ], "critical_questions": [ "Comment prévoyez-vous de distinguer empiriquement la signature de votre goulot d'étranglement proposé comme moteur de l'introgression de l'explication bien plus parcimonieuse d'une mutation *de novo* suivie d'une expansion clonale sous sélection médicamenteuse, en particulier compte tenu des faibles taux de recombinaison ?", "Votre mécanisme repose sur l'existence d'allèles de résistance « préexistants » à des fréquences de 0,001-0,05. Quelles preuves génomiques directes existent pour une telle variation présente dans les populations cliniques pour les cibles antifongiques clés, étant donné que même un séquençage profond d'échantillons de patients peut ne pas capturer les variants présents dans une future sous-population soumise à un goulot d'étranglement ?" ], "recommendation": "Pour être crédible, les auteurs doivent d'abord démontrer la faisabilité de l'étape d'introgression. Cela nécessite un système d'évolution expérimentale dans lequel deux lignées marquées (l'une portant un allèle de résistance ayant dérivé) sont co-cultivées sans sélection, avec des taux de recombinaison et des fréquences d'introgression mesurés directement par séquençage. Sans validation empirique de cette étape clé, limitante, l'hypothèse demeure un scénario théorique intéressant mais non étayé." }, { "reviewer_persona": "industrialist", "overall_score": 4.5, "verdict": "weak_reject", "strengths": [ "Adresse un besoin critique non satisfait dans la lutte antifongique : la prediction de l'emergence de resistances 'stochastiques' echappant aux modeles deterministes, visant directement les departements R&D des grands groupes pharmaceutiques (Pfizer, Gilead, MSD) et les agences de sante publique (CDC, ECDC).", "Avantage competitif potentiel dans la surveillance epidemiologique : une plateforme predictive basee sur ce mecanisme pourrait identifier les souches a 'haut risque d'introgression' avant leur emergence clinique, offrant un delai d'alerte de 6-18 mois sur les methodes actuelles de sequencage reactif." ], "weaknesses": [ "Marche adressable trop niche et difficile a monetiser directement. Le client final (hopital) ne paie pas pour des modeles evolutifs, et le transfert vers un kit diagnostique ou un logiciel SaaS rencontre une competition farouche d'acteurs etablis (QIAGEN, bioMerieux) avec des barrieres reglementaires (FDA/CE-IVD) insurmontables a court terme.", "Le TRL est extremement bas (2-3). La voie de commercialisation la plus realiste est la vente de service de R&D ou de licence de propriete intellectuelle a un grand pharma, un modele a faible marge et a cycle de vente long (>3 ans), avec un ROI incertain face aux priorites internes des acheteurs potentiels." ], "critical_questions": [ "Quel est le business model concret ? Vendez-vous un algorithme (SaaS aux labos academiques), un service d'analyse contractuelle (CRO), ou visez-vous un partenariat de co-developpement avec un acteur du diagnostic ? Chaque voie exige des competences et un capital radicalement differents.", "Quelle est la strategie de protection IP ? Le mecanisme evolutif lui-meme n'est pas brevetable. Seul un protocole experimental specifique ou un algorithme predictif unique pourrait l'etre, offrant une barriere a l'entree faible face a des concurrents mieux capitalises." ], "recommendation": "Reorienter l'hypothese vers un service de recherche sous contrat (CRO) pour les departements de resistance antifongique des grands pharmas, en utilisant le protocole valide comme preuve de concept. Parallellement, developper un algorithme predictif minimal (MVP) et le proposer en acces libre pour etablir un standard academique et capturer l'expertise, en visant a long terme une licence exclusive pour un developpeur de logiciel de surveillance epidemiologique (ex : BioNumerics).", "confidence": 0.75 }, { "reviewer_persona": "funding_strategist", "overall_score": 6.5, "verdict": "weak_accept", "strengths": [ "Hypothèse mécanistique originale qui relie la génétique des populations, l'écologie évolutive et la santé publique, un angle très apprécié dans les appels interdisciplinaires.", "Protocole bien structuré avec des critères GO/NO-GO clairs, démontrant une approche par étapes et une gestion des risques adaptée à un projet exploratoire." ], "weaknesses": [ "TRL actuel très bas (TRL 1-2). Le budget et la timeline proposés correspondent à une preuve de concept préliminaire, insuffisante pour un appel collaboratif majeur type Horizon Europe.", "Le narratif actuel est trop focalisé sur la validation technique. Pour un appel compétitif, il faut renforcer l'impact sociétal (résistance aux antifongiques = menace sanitaire mondiale) et le lien avec les données cliniques/épidémiologiques existantes." ], "critical_questions": [ "Quelle est la preuve préliminaire, au-delà de la simulation, que ces événements de goulot d'étranglement se produisent dans des niches cliniques ou environnementales réelles (biofilms, infection chronique, traitement antifongique) ?", "Le consortium idéal manque d'un partenaire clinique ou de santé publique pour valider la pertinence des souches et le modèle écologique. Qui pourrait remplir ce rôle pour renforcer la proposition ?" ], "recommendation": "Cibler d'abord un financement de démarrage pour atteindre un TRL 3-4 avec des données expérimentales solides sur un modèle fongique. En parallèle, constituer un consortium exploratoire avec un modélisateur, un généticien des populations fongiques et un clinicien/microbiologiste hospitalier. Présenter ensuite le projet comme une recherche fondamentale avec un potentiel de transformation pour la surveillance et la gestion de la résistance.", "confidence": 0.8, "funding_programs": [ { "program": "ERC Starting Grant / ERC Proof of Concept", "agency": "European Research Council", "fit_score": 0.7, "typical_budget": "€1.5M pour StG ; €150k pour PoC", "success_rate": "~13% (StG)", "next_deadline": "Octobre 2025 (StG, estimation)", "rationale": "L'hypothèse est suffisamment risquée, fondamentale et novatrice pour un ERC. Le cœur du projet (dérive génétique, fixation, introgression) est de la science de base d'excellence. Une Starting Grant pourrait financer l'ensemble du protocole étendu. Un Proof of Concept serait adapté si un chercheur ERC en poste voulait développer cet axe." }, { "program": "ANR AAPG Générique - Jeunes Chercheuses et Jeunes Chercheurs (JCJC)", "agency": "Agence Nationale de la Recherche (France)", "fit_score": 0.85, "typical_budget": "€150k - €300k", "success_rate": "~15-20%", "next_deadline": "Fin 2024 / début 2025 (estimation)", "rationale": "Fit parfait pour le budget et la maturité. L'appel JCJC vise explicitement des projets exploratoires et risqués portés par des chercheurs en début de carrière. Le protocole proposé (20k-80k) correspond à une sous-partie d'un projet JCJC, qui permettrait de financer intégralement les phases 2 et 3, avec des moyens pour du séquençage et du personnel." }, { "program": "EMBO Installation Grants / EMBO Scientific Exchange Grants", "agency": "European Molecular Biology Organization", "fit_score": 0.65, "typical_budget": "€50k - €150k (Installation) ; montants plus faibles (Exchange)", "success_rate": "Variable, compétitif", "next_deadline": "Février 2025 (Installation, estimation)", "rationale": "L'EMBO finance l'excellence en biologie moléculaire, y compris la biologie évolutive et fongique. Un Installation Grant (pour chercheurs revenant en Europe) pourrait couvrir le budget de démarrage. Un Exchange Grant serait idéal pour initier une collaboration avec un laboratoire expert en génomique des populations de champignons pathogènes, étape clé pour bâtir le futur consortium." } ] } ], "meta_review": { "consensus_score": 6.18, "verdict": "publish_brief", "key_consensus": [ "L'hypothèse propose une synthèse intellectuelle originale et valable entre la théorie de la dérive génétique, les effets de goulot d'étranglement et l'évolution de la résistance antifongique, méritant une investigation plus poussée.", "Le protocole expérimental proposé est bien structuré, avec une approche séquentielle et des critères GO/NO-GO clairs, représentant une bonne pratique méthodologique.", "Les préoccupations majeures portent sur la plausibilité biologique de deux paramètres clés : le taux de recombinaison supposé (≥ 10⁻⁸) et la distribution des effets fitness (|s| < 0.01) pour les allèles de résistance. Ces points sont identifiés comme des risques potentiels de rupture de la chaîne causale." ], "key_disagreements": [ "L'évaluation de la maturité et du potentiel de l'hypothèse : le méthodologiste et l'expert du domaine recommandent l'acceptation/faible acceptation pour tester les prédictions, tandis que le contrarien et l'industriel recommandent le rejet, jugeant les étapes clés (introgression) peu plausibles ou non commercialisables.", "L'interprétation des faiblesses : pour certains, ce sont des points à affiner dans le protocole ; pour le contrarien, ce sont des « raisons d'échec » (fail reasons) qui invalident le mécanisme central sans validation expérimentale préalable.", "La finalité : vision académique de test d'une hypothèse fondamentale vs. attente d'une application translationnelle ou commerciale immédiate." ], "critical_path": "La validation expérimentale directe de l'étape d'introgression par recombinaison homologue. Le succès ou l'échec de l'hypothèse repose entièrement sur la démonstration que cette étape est biologiquement plausible et mesurable dans des systèmes fongiques pathogènes pertinents, avec des taux de recombinaison et des coûts fitness réalistes.", "final_recommendation": "Le panel reconnaît la créativité et la rigueur méthodologique de la proposition, mais le scepticisme sur la plausibilité biologique du mécanisme central, particulièrement l'étape d'introgression, est substantiel et bien fondé. À cette deuxième itération, sans preuve préliminaire solide pour étayer les paramètres critiques (DFE, taux de recombinaison), l'hypothèse ne remplit pas le seuil de confiance nécessaire pour une publication en l'état. Il est recommandé d'abandonner cette formulation spécifique et de recentrer les efforts sur la collecte de données empiriques concernant les effets fitness des allèles de résistance et les taux de recombinaison dans des niches à goulot d'étranglement, avant de proposer un nouveau modèle mécanistique.", "brief_quality_gate": false, "revision_guidance": [], "llm_verdict": "reject", "llm_consensus_score": 6.14, "verdict_override_reason": "Python threshold override: consensus 6.18 at iter 2 → publish_brief (LLM said reject)" } }, "vulgarization_fr": { "title_fr": "Quand le hasard fabrique des champignons résistants : une hypothèse audacieuse", "hypothesis_in_brief": "L'hypothèse propose que, dans de petites populations isolées de champignons pathogènes (par exemple dans un biofilm ou un tissu infecté), le hasard puisse fixer des gènes de résistance aux antifongiques, même si ces gènes coûtent un peu de fitness. Ces gènes pourraient ensuite se propager à la population générale par recombinaison génétique, laissant des traces détectables dans les arbres phylogénétiques.", "why_it_matters": "La résistance aux antifongiques est une menace croissante pour les patients immunodéprimés. Les modèles actuels supposent que la résistance se développe principalement sous la pression des médicaments. Si cette hypothèse est correcte, des résistances pourraient émerger dans des niches isolées, même sans exposition au traitement, et se propager ensuite. Cela changerait la façon dont on surveille et prédit l'apparition de résistances en milieu clinique.", "imagine_that": "Imaginez une petite équipe de randonneurs bloquée dans une vallée isolée par un éboulement. Parmi eux, une personne porte une mutation génétique rare qui la rend résistante à un futur virus. Par simple hasard, cette personne transmet ce gène à ses descendants, et quand l'éboulement est dégagé, certains de ces descendants migrent vers la grande ville voisine et y introduisent ce gène. La résistance se répand alors non pas parce qu'elle était avantageuse au départ, mais parce que le hasard l'a fixée dans un petit groupe isolé.", "concretely": { "intro": "Pour tester cette hypothèse, une série d'expériences est prévue, allant de simulations informatiques à des manipulations en laboratoire sur la levure pathogène Candida auris.", "phase1": "Des simulations informatiques modélisent des populations de taille réduite (50 à 200 individus) pour vérifier si le hasard peut fixer des allèles de résistance à faible coût. Les résultats seront comparés à des données génétiques de souches cliniques.", "phase2": "En laboratoire, une souche de Candida auris est modifiée pour porter un marqueur fluorescent et une mutation de résistance connue. Des populations de taille réduite sont cultivées pour observer si la résistance se fixe par hasard.", "phase3": "Les lignées où la résistance s'est fixée sont mises en contact avec une population plus large et sensible, pour mesurer la fréquence et la vitesse de propagation de la résistance par recombinaison. Des analyses phylogénétiques vérifieront si des discordances apparaissent entre les arbres génétiques." }, "reviewers_say": "Le panel reconnaît l'originalité de l'hypothèse, qui combine génétique des populations et mycologie clinique, et salue la rigueur du protocole avec ses étapes séquentielles et ses critères GO/NO-GO. Cependant, plusieurs experts doutent de la plausibilité de l'étape d'introgression : le taux de recombinaison proposé est peut-être trop faible pour que la résistance se propage efficacement, et le coût de fitness des mutations de résistance pourrait être sous-estimé. Le verdict global est « publier le brief » avec un score consensus de 6,18/10, mais pour y croire, il faudrait des preuves expérimentales solides sur la distribution des coûts de fitness et sur la fréquence réelle des recombinaisons entre lignées divergentes de champignons pathogènes." }, "vulgarization_en": { "title": "When chance produces resistant fungi: a bold hypothesis", "hypothesis_in_brief": "The hypothesis proposes that, in small isolated populations of pathogenic fungi (for example in a biofilm or infected tissue), chance may fix antifungal resistance genes, even if these genes cost a little fitness. These genes could then spread to the general population through genetic recombination, leaving detectable traces in phylogenetic trees.", "why_it_matters": "Antifungal resistance is a growing threat to immunocompromised patients. Current models assume that resistance develops primarily under drug pressure. If this hypothesis is correct, resistance could emerge in isolated niches, even without treatment exposure, and subsequently spread. This would change how the emergence of resistance is monitored and predicted in clinical settings.", "imagine_that": "Imagine a small team of hikers trapped in a valley isolated by a landslide. Among them, one person carries a rare genetic mutation that makes her resistant to a future virus. By pure chance, this person passes the gene on to her descendants, and when the landslide is cleared, some of those descendants migrate to the nearby city and introduce the gene there. The resistance then spreads not because it was advantageous at the outset, but because chance fixed it within a small isolated group.", "reviewers_say": "The panel recognises the originality of the hypothesis, which combines population genetics and clinical mycology, and commends the rigour of the protocol with its sequential stages and GO/NO-GO criteria. However, several experts question the plausibility of the introgression stage: the proposed recombination rate may be too low for resistance to spread efficiently, and the fitness cost of resistance mutations may be underestimated. The overall verdict is \"publish the brief\" with a consensus score of 6.18/10, but for this to be credible, robust experimental evidence would be required on the distribution of fitness costs and on the actual frequency of recombination between divergent lineages of pathogenic fungi.", "concretely": { "intro": "To test this hypothesis, a series of experiments is planned, ranging from computer simulations to laboratory manipulations on the pathogenic yeast Candida auris.", "phase1": "Computer simulations model small populations (50 to 200 individuals) to test whether chance can fix low-cost resistance alleles. The results will be compared against genetic data from clinical strains.", "phase2": "In the laboratory, a strain of Candida auris is modified to carry a fluorescent marker and a known resistance mutation. Populations of reduced size are cultured to observe whether resistance becomes fixed by chance.", "phase3": "Lines in which resistance has become fixed are placed in contact with a larger, susceptible population, to measure the frequency and speed of resistance spread through recombination. Phylogenetic analyses will verify whether discordances arise between genetic trees." } }, "panel_en": { "reviews": [ { "reviewer_persona": "methodologist", "overall_score": 8.2, "verdict": "accept", "confidence": 0.88, "strengths": [ "The protocol adopts a staged and cautious approach, with an in silico phase to validate theoretical predictions before committing to costly and lengthy experiments. This sequential design with explicit GO/NO-GO criteria is an excellent methodological practice.", "The experimental design incorporates appropriate controls at each phase (e.g. large populations in Phase 2, de novo mutation control in Phase 3) and uses high numbers of biological replicates (100 bottleneck lines), which strengthens the internal validity and the robustness of the conclusions.", "The hypothesis is formulated in a precise and falsifiable manner, with clear quantitative predictions and adequate measurement methods (fixation probability, Robinson-Foulds distances, allele frequency tracking). The distinction between the effects of drift and selection is well articulated." ], "weaknesses": [ "The statistical power for Phase 2, although reasonable (100 replicates), may be marginal for detecting a fixation probability of 0.05. With P=0.05, approximately 5 fixation events per 100 are expected. Random fluctuation could readily yield 2–3 events, leading to a false NO-GO. A more formal power analysis conducted in advance is required.", "The risk of measurement bias in Phase 3 is underestimated. Tracking allele frequency by pool sequencing every 50 generations may miss transient dynamics or be biased by differences in amplification efficiency. Control by sequencing individual isolates at key time points would be a useful complement.", "The protocol relies heavily on accurate measurement of the selection coefficient (s = -0.005) for the marked resistance allele. An error in this measurement (risk noted [medium]) would invalidate the central interpretation of Phase 2. The method for measuring 's' is not described and should be detailed, together with an estimate of the confidence interval." ], "critical_questions": [ "For Phase 2, what is the exact statistical analysis plan for comparing the probability of fixation between bottlenecks and large populations? Is an exact Fisher test on a 2x2 contingency table (fixed vs not fixed; bottleneck vs large) planned, and has its statistical power been calculated given the low number of expected events?", "In Phase 3, how will the effect of introgression by homologous recombination be isolated and quantified specifically, relative to other potential mechanisms of genetic transfer (e.g. gene conversion, horizontal chromosome transfer) or to secondary selection on compensatory mutations? The design with linked markers is sound, but additional controls may be necessary.", "Is the phylogenetic discordance criterion (≥15% of nodes) biologically relevant and statistically robust? Has a sensitivity analysis for this threshold been planned, and how will discordance due to introgression be distinguished from discordance due to convergent evolution or mutational saturation on the resistance gene?" ], "recommendation": "Acceptance of the protocol is recommended with minor revisions. The design is broadly sound, innovative and methodologically rigorous. Before Phase 2 commences, it is imperative to: 1) perform a formal statistical power analysis and consider increasing the number of replicates to 150–200 for the bottleneck condition; 2) detail and validate the protocol for measuring the selection coefficient (s) with technical and biological replicates. Phase 3 should include an additional control plan to verify the homologous recombination mechanism (for example, by knocking out a key recombination gene in a control line)." }, { "reviewer_persona": "domain_expert", "overall_score": 7.0, "verdict": "weak_accept", "confidence": 0.8, "strengths": [ "The hypothesis successfully integrates three well-established but often distinct theoretical frameworks — the nearly neutral theory (Ohta), founder-effect and bottleneck dynamics (Mayr), and network phylogenetics — into a coherent mechanistic model for a pressing applied problem (antifungal resistance). This synthesis is intellectually compelling.", "The proposed mechanism is biologically plausible and accords with known fungal ecology. The recognition of clinical and ecological niches (biofilms, specific tissues) as potential sites of severe bottlenecks is judicious and demonstrates an understanding of fungal population biology that goes beyond simple in vitro models.", "The quantitative framework (Nₑ = 50–200, |s| < 0.01, recombination rate ≥ 10⁻⁸) provides testable predictions and moves the hypothesis beyond a purely verbal model. The prediction of phylogenetic discordance ≥ 15% constitutes a concrete and falsifiable outcome for genomic studies." ], "weaknesses": [ "The evidence base is more analogical than direct. The founding article (Joly, 2010) addresses a general model of speciation, not the evolution of resistance in fungi. The other citations provide supporting context (diversity, recombination, epidemiology) but do not constitute evidence for the proposed causal chain. The hypothesis currently lacks direct empirical support derived from fungal systems.", "The key parameters are presented as postulates but constitute critical unknowns. The Distribution of Fitness Effects (DFE) of antifungal resistance mutations in vivo is poorly characterised; certain resistance mutations may have |s| >> 0.01, rendering drift-mediated fixation improbable. Likewise, the recombination rate between divergent lineages under natural conditions is often well below 10⁻⁸, which could break the introgression step.", "The hypothesis may underestimate the role of direct selection. In clinical settings, bottlenecks (for example, transmission) often coincide with drug exposure (prophylaxis or treatment), creating a scenario in which selection for resistance is strong and simultaneous. Distinguishing the effects of drift from weak background selection in these complex environments constitutes a major methodological challenge." ], "critical_questions": [ "Given that many antifungal-resistance mutations (for example, in ERG11) are known to confer fitness costs significantly greater than 1% in vitro, how can the central postulate of |s| < 0.01 be justified for the relevant alleles in the proposed niche environments? Can estimates from the literature or preliminary data be provided?", "The hypothesis posits that introgression through homologous recombination constitutes a key final step. However, many pathogenic fungi such as Candida auris exhibit predominantly clonal population structures, with limited recombination between major clades. How would the mechanism operate in such species, or is the hypothesis specific to pathogens that recombine?", "How can the signature of this \"bottleneck–fixation–introgression\" model be operationally distinguished from alternative models, such as (a) selection on pre-existing variation in a large population, or (b) de novo mutation and selection during the bottleneck event itself, using standard genomic datasets (for example, a collection of clinical isolates)?" ], "recommendation": "The hypothesis presents an innovative and theoretically sound synthesis that merits investigation. The panel recommends proceeding with a targeted research programme to test its central postulates. Priority should be given to: 1) Quantifying the fitness effects of resistance alleles under relevant host-mimicking and drug-free conditions, in order to refine the DFE. 2) Developing population-genomic simulations to establish the phylogenetic signals expected (network discordance) under this model relative to alternatives. 3) Targeted sequencing of fungal populations from putative bottleneck niches (for example, biofilms on a single host over time) in order to seek direct evidence of drift-induced allele-frequency shifts." }, { "reviewer_persona": "contrarian", "overall_score": 4.5, "verdict": "weak_reject", "confidence": 0.85, "strengths": [ "The hypothesis elegantly bridges population-genetics theory (drift in bottlenecks) and a pressing clinical problem (antifungal resistance) by proposing a non-adaptive pathway that is often overlooked.", "The proposed predictions are formulated quantitatively and are in principle testable, moving beyond purely correlational observations to propose specific experiments and bioinformatic signatures." ], "weaknesses": [ "FAIL REASON #1: The proposed recombination rate (≥ 10⁻⁸ events/bp/generation) is probably insufficient for effective introgression within the proposed timeframe. Many pathogenic fungi, including Candida auris, exhibit predominantly clonal population structures, with rare and restricted recombination. The probability that a rare allele, having drifted within a minute subpopulation, successfully recombines into a genetically distinct progenitor background before being lost again is extremely low, which makes the causal chain from step 3 to step 4 the critical point of failure.", "FAIL REASON #2: The assumed distribution of the fitness cost (|s| < 0.01) is optimistic and probably unrealistic for many resistance alleles in a *drug-free* environment, which is the condition relevant for drift to outweigh selection. Known ERG11 mutations often carry a measurable fitness cost in vitro. If the true cost is s = -0.05, rather than -0.005, drift within an Nₑ of 200 becomes negligible, and the allele is eliminated even within the bottleneck.", "FAIL REASON #3: The predicted phylogenetic discordance (≥ 15 %) is a post-hoc pattern expected from numerous processes (for example, convergent evolution, horizontal gene transfer, incomplete lineage sorting). Its detection does not validate the proposed bottleneck-introgression mechanism. It is a prediction subject to confounding factors; the hypothesis lacks a unique and falsifiable signature that would distinguish its specific mechanism from these alternatives." ], "critical_questions": [ "How is it planned to distinguish empirically the signature of the proposed bottleneck as the driver of introgression from the far more parsimonious explanation of a *de novo* mutation followed by clonal expansion under drug selection, particularly given the low recombination rates?", "The proposed mechanism rests on the existence of \"pre-existing\" resistance alleles at frequencies of 0.001–0.05. What direct genomic evidence exists for such standing variation in clinical populations for the key antifungal targets, given that even deep sequencing of patient samples may fail to capture variants present in a future subpopulation undergoing a bottleneck?" ], "recommendation": "To be credible, the authors must first demonstrate the feasibility of the introgression step. This requires an experimental evolution system in which two marked lineages (one carrying a resistance allele that has arisen) are co-cultured without selection, with recombination rates and introgression frequencies measured directly by sequencing. Without empirical validation of this key, rate-limiting step, the hypothesis remains an interesting but unsupported theoretical scenario." }, { "reviewer_persona": "industrialist", "overall_score": 4.5, "verdict": "weak_reject", "confidence": 0.75, "strengths": [ "Addresses a critical unmet need in antifungal control: the prediction of the emergence of 'stochastic' resistance escaping deterministic models, aimed directly at the R&D departments of major pharmaceutical groups (Pfizer, Gilead, MSD) and public health agencies (CDC, ECDC).", "Potential competitive advantage in epidemiological surveillance: a predictive platform based on this mechanism could identify strains at 'high risk of introgression' before their clinical emergence, offering a warning lead time of 6–18 months over current reactive sequencing methods." ], "weaknesses": [ "The addressable market is too niche and difficult to monetise directly. The end customer (hospital) does not pay for evolving models, and transfer to a diagnostic kit or SaaS software encounters fierce competition from established players (QIAGEN, bioMérieux) with regulatory barriers (FDA/CE-IVD) that are insurmountable in the short term.", "The TRL is extremely low (2–3). The most realistic commercialisation path is the sale of R&D services or licensing of intellectual property to a large pharmaceutical company, a low-margin model with a long sales cycle (>3 years), with uncertain ROI given the internal priorities of potential buyers." ], "critical_questions": [ "What is the concrete business model? Is an algorithm to be sold (SaaS to academic laboratories), a contract analysis service (CRO), or is a co-development partnership with a diagnostics player envisaged? Each route demands radically different expertise and capital.", "What is the IP protection strategy? The evolutionary mechanism itself is not patentable. Only a specific experimental protocol or a unique predictive algorithm could be, offering a weak barrier to entry against better-capitalised competitors." ], "recommendation": "Redirect the hypothesis towards a contract research organisation (CRO) service for the antifungal resistance departments of large pharmaceutical companies, using the validated protocol as a proof of concept. In parallel, develop a minimal predictive algorithm (MVP) and offer it under open access to establish an academic standard and capture expertise, with a long-term view to an exclusive licence for a developer of epidemiological surveillance software (e.g. BioNumerics)." }, { "reviewer_persona": "funding_strategist", "overall_score": 6.5, "verdict": "weak_accept", "confidence": 0.8, "funding_programs": [ { "program": "ERC Starting Grant / ERC Proof of Concept", "agency": "European Research Council", "fit_score": 0.7, "typical_budget": "€1.5M pour StG ; €150k pour PoC", "success_rate": "~13% (StG)", "next_deadline": "Octobre 2025 (StG, estimation)", "rationale": "L'hypothèse est suffisamment risquée, fondamentale et novatrice pour un ERC. Le cœur du projet (dérive génétique, fixation, introgression) est de la science de base d'excellence. Une Starting Grant pourrait financer l'ensemble du protocole étendu. Un Proof of Concept serait adapté si un chercheur ERC en poste voulait développer cet axe." }, { "program": "ANR AAPG Générique - Jeunes Chercheuses et Jeunes Chercheurs (JCJC)", "agency": "Agence Nationale de la Recherche (France)", "fit_score": 0.85, "typical_budget": "€150k - €300k", "success_rate": "~15-20%", "next_deadline": "Fin 2024 / début 2025 (estimation)", "rationale": "Fit parfait pour le budget et la maturité. L'appel JCJC vise explicitement des projets exploratoires et risqués portés par des chercheurs en début de carrière. Le protocole proposé (20k-80k) correspond à une sous-partie d'un projet JCJC, qui permettrait de financer intégralement les phases 2 et 3, avec des moyens pour du séquençage et du personnel." }, { "program": "EMBO Installation Grants / EMBO Scientific Exchange Grants", "agency": "European Molecular Biology Organization", "fit_score": 0.65, "typical_budget": "€50k - €150k (Installation) ; montants plus faibles (Exchange)", "success_rate": "Variable, compétitif", "next_deadline": "Février 2025 (Installation, estimation)", "rationale": "L'EMBO finance l'excellence en biologie moléculaire, y compris la biologie évolutive et fongique. Un Installation Grant (pour chercheurs revenant en Europe) pourrait couvrir le budget de démarrage. Un Exchange Grant serait idéal pour initier une collaboration avec un laboratoire expert en génomique des populations de champignons pathogènes, étape clé pour bâtir le futur consortium." } ], "strengths": [ "An original mechanistic hypothesis linking population genetics, evolutionary ecology and public health — an angle highly favoured in interdisciplinary calls.", "A well-structured protocol with clear GO/NO-GO criteria, demonstrating a stepwise approach and risk management suited to an exploratory project." ], "weaknesses": [ "The current TRL is very low (TRL 1-2). The proposed budget and timeline correspond to a preliminary proof of concept, insufficient for a major collaborative call such as Horizon Europe.", "The current narrative is too focused on technical validation. For a competitive call, the societal impact (antifungal resistance = a global health threat) and the link to existing clinical/epidemiological data require strengthening." ], "critical_questions": [ "What preliminary evidence, beyond simulation, indicates that these bottleneck events occur in real clinical or environmental niches (biofilms, chronic infection, antifungal treatment)?", "The ideal consortium lacks a clinical or public-health partner to validate the relevance of the strains and the ecological model. Who could fill this role to strengthen the proposal?" ], "recommendation": "The initial aim is to secure seed funding to reach TRL 3–4 with robust experimental data on a fungal model. In parallel, an exploratory consortium is to be assembled, comprising a modeller, a fungal population geneticist, and a hospital clinician/microbiologist. The project is then to be presented as fundamental research with transformative potential for the surveillance and management of resistance." } ], "meta_review": { "consensus_score": 6.18, "verdict": "publish_brief", "brief_quality_gate": false, "llm_verdict": "reject", "llm_consensus_score": 6.14, "verdict_override_reason": "Python threshold override: consensus 6.18 at iter 2 → publish_brief (LLM said reject)", "key_consensus": [ "The hypothesis proposes an original and valid intellectual synthesis between genetic drift theory, bottleneck effects and the evolution of antifungal resistance, warranting further investigation.", "The proposed experimental protocol is well structured, with a sequential approach and clear GO/NO-GO criteria, representing good methodological practice.", "The major concerns relate to the biological plausibility of two key parameters: the assumed recombination rate (≥ 10⁻⁸) and the distribution of fitness effects (|s| < 0.01) for resistance alleles. These points are identified as potential risks of breaking the causal chain." ], "key_disagreements": [ "The assessment of the maturity and potential of the hypothesis: the methodologist and the domain expert recommend acceptance/weak acceptance for testing the predictions, whereas the contrarian and the industrialist recommend rejection, judging the key steps (introgression) to be implausible or non-commercialisable.", "The interpretation of the weaknesses: for some, these are points to be refined in the protocol; for the contrarian, they are \"fail reasons\" that invalidate the central mechanism without prior experimental validation.", "The purpose: an academic vision of testing a fundamental hypothesis vs. the expectation of an immediate translational or commercial application." ], "revision_guidance": [], "critical_path": "Direct experimental validation of the homologous-recombination introgression step. The success or failure of the hypothesis rests entirely on the demonstration that this step is biologically plausible and measurable in relevant pathogenic fungal systems, with realistic recombination rates and fitness costs.", "final_recommendation": "The panel recognises the creativity and methodological rigour of the proposal, but scepticism regarding the biological plausibility of the central mechanism, particularly the introgression step, is substantial and well founded. At this second iteration, in the absence of robust preliminary evidence to support the critical parameters (DFE, recombination rate), the hypothesis does not meet the confidence threshold required for publication as it stands. It is recommended that this specific formulation be abandoned and that efforts be refocused on the collection of empirical data concerning the fitness effects of resistance alleles and recombination rates in bottleneck niches, before a new mechanistic model is proposed." } } }